Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Spain

Marie Skłodowska-Curie Action · Running

IMPROVE IMaging PROstate cancer using ViscoElastic biomarkers and a novel transurethral viscoelastic elastography procedure

Coordinator
Universidad De Granada, Spain
Runs
1 September 2023 to 31 August 2025
Status
Running
EU funding
€181k
Total cost
—
Partners
2 organisations in 2 countries
Type
Marie Skłodowska-Curie Action
Grant agreement
101062897

What the project is doing

In the project's own words, from its summary on CORDIS.

IMPROVE aims to demonstrate the potentiality of Transurethral Shear Wave Viscoelastic Elastography (TUSWAVE) for ‘improving’ the diagnosis of Prostate Cancer (PCa) by identifying it through a new set of biomarkers based on the fractional viscoelastic properties of the prostate. TUSWAVE is a novel concept based on the transmission and reception of shear waves in the prostate through the urethra. Most prostatic tumours are stiffer than normal surrounding tissue, which perturbs the propagation of shear waves.

The perturbed waves carry information about the location and changes in the viscoelastic properties of the tumours. IMPROVE aims to further study the correlation between diagnosis features of prostate cancer, such as grade, stage and vascularisation, with shear fractional viscoelastic properties of the prostate, i.e. the shear modulus, the shear viscosity and the fractional-order parameter. To achieve IMPROVE’s goal three main work packages are proposed.

First, the development of a 3D anatomically realistic wave propagation model validated in ex vivo human prostate; second, the characterisation of the fractional viscoelastic properties of prostatic tissue under different pathological conditions using Shear Wave Elastography and validated against independent techniques; and finally, the development of a preliminary Artificial Intelligence-based image reconstruction method for TUSWAVE.

A large database of prostate cancer clinical scenarios will be generated using the data from the characterisation study and the 3D wave propagation model. This database will be used to train and test the image reconstruction method. Prostate-like phantoms will be used to test the performance of the image reconstruction method. IMPROVE will take TUSWAVE towards a pre-clinical studies stage. IMPROVE is aligned with the mission area 'cancer' set on Horizon Europe.

Topics

Who is involved

OrganisationCityCountryRole
Universidad De GranadaGranadaSpainCoordinator
University College LondonLondonUnited KingdomAssociatedpartner

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI